ClearNote Health
ClearNote Health develops epigenomic, blood-based diagnostics that detect cancer early by measuring 5-hydroxymethylcytosine (5hmC) signatures in cell-free DNA. The company operates an automated clinical laboratory, publishes peer-reviewed validation data, conducts clinical studies, and offers epigenomic profiling services to support translational drug development and biopharma partnerships.
Industries
Nr. of Employees
small (1-50)
ClearNote Health
Products
Pancreatic cancer cfDNA early detection test
A blood-based cfDNA assay that measures 5hmC epigenomic biomarkers to detect pancreatic cancer in high-risk patients.
Ovarian cancer cfDNA early detection test
A blood-based cfDNA assay using 5hmC biomarker analysis intended to detect ovarian cancer in women at elevated risk.
Pancreatic cancer cfDNA early detection test
A blood-based cfDNA assay that measures 5hmC epigenomic biomarkers to detect pancreatic cancer in high-risk patients.
Ovarian cancer cfDNA early detection test
A blood-based cfDNA assay using 5hmC biomarker analysis intended to detect ovarian cancer in women at elevated risk.
Services
Epigenomic profiling for translational research
Genome-wide 5hmC profiling of plasma cfDNA to support drug discovery, patient selection, monitoring of therapy response and resistance, and longitudinal translational studies.
Epigenomic profiling for translational research
Genome-wide 5hmC profiling of plasma cfDNA to support drug discovery, patient selection, monitoring of therapy response and resistance, and longitudinal translational studies.
Expertise Areas
- Epigenomic-based early cancer detection
- Liquid biopsy and cell-free DNA analysis
- Biomarker discovery and analytical validation
- Clinical laboratory operations and automation
Key Technologies
- 5-hydroxymethylcytosine (5hmC) profiling
- Cell-free DNA (cfDNA) analysis
- Whole-genome sequencing
- 5hmC enrichment workflows